Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

U.K.-based ad agency DAIVID said Pfizer had a strong, positive message with its ad and scored high with intense positive emotions. The commercial was also a top performer with spikes in positive ...

Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

Shareholders of Pfizer may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.